Solid Biosciences (SLDB) Cash from Investing Activities (2017 - 2026)

Solid Biosciences has disclosed Cash from Investing Activities across 10 years of filings, most recently posting $44.8 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $44.8 million, up 262.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.8 million (up 372.13% YoY), and the FY2025 annual result was -$58.5 million, down 263.38% from the prior year.
• Cash from Investing Activities came in at $44.8 million for Q1 2026 at Solid Biosciences, down from $47.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $66.1 million in Q4 2022 to a low of -$59.6 million in Q2 2022.
• The 5-year median for Cash from Investing Activities is -$5.2 million (2024), against an average of $2.3 million.
• Across the five-year window, Cash from Investing Activities soared 107937.14% in 2022 and plunged 532.38% in 2025, its largest moves.
• Solid Biosciences' Cash from Investing Activities stood at $66.1 million in 2022, then slumped by 31.47% to $45.3 million in 2023, then fell by 14.86% to $38.6 million in 2024, then rose by 21.9% to $47.0 million in 2025, then decreased by 4.8% to $44.8 million in 2026.
• The last three Cash from Investing Activities figures came in at $44.8 million (Q1 2026), $47.0 million (Q4 2025), and -$45.3 million (Q3 2025), per Business Quant data.